Table 2.

Bleeding Rates with Long-Term Combination Therapy in Selected Clinical Trials

TrialPatient PopulationDuration (months)Major and Minor Bleeds
Combination Therapy (%)Monotherapy (%)
CURE (9)NSTEMI98.85.1
CREDO (11)PCI1214.112.3
CHARISMA (3)CAD283.82.6
MATCH (5)CVA185.11.6*
TRITON (2)ACS with PCI155.0/3.8NA
  • * Clopidogrel monotherapy.

  • Prasugrel plus aspirin.

  • CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; CREDO, Clopidogrel for the Reduction of Events During Observation; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; MATCH, Management of Atherothrombosis with Clopidogrel in High-Risk Patients; TRITON, Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel; NSTEMI, non-ST-segment elevation myocardial infarction; CAD, coronary artery disease; CVA, cardiovascular accident; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention.